Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors
Erica Pietroluongo(University of Naples Federico II), Mario Giuliano(Regione Campania), Monica Gelzo(Ceinge Biotecnologie Avanzate (Italy)), Aldo Caltavituro(University of Naples Federico II), Gustavo Cernera(Ceinge Biotecnologie Avanzate (Italy)), Rocco Morra(Federico II University Hospital), Angela Viggiano(Federico II University Hospital), Giovannella Palmieri(Regione Campania), Pietro De Placido(University of Naples Federico II), Carmine De Angelis(Baylor College of Medicine), Daniela Terracciano(Federico II University Hospital), Vitantonio Del Deo(Regione Campania), Anna Maria Malfitano(University of Naples Federico II), Grazia Arpino(University of Naples Federico II), Roberto Bianco(Federico II University Hospital), Marianna Tortora(Regione Campania), Margaret Ottaviano(University of Naples Federico II), Pietro Formisano(Federico II University Hospital), Bianca Maria Veneziani(Federico II University Hospital), Sabino De Placido, Michele Francesco Di Tolla(Federico II University Hospital), Giuseppe Castaldo(Federico II University Hospital), Claudia Martinelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Rosaria Saponaro(Federico II University Hospital), Roberto Buonaiuto(Scuola Superiore Meridionale)
Cited by 8
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282